Inflammation and scarring in pulmonary TB: the INFIN-TB study
Official title: Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study
Funded at Emory University · NIH-11551510 · Data updated 2026-11-12
A study of people with newly diagnosed drug-susceptible TB, with and without HIV, to understand why some patients develop long-term lung problems after TB and how to prevent them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 7, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $48,153 |
| NIH project number | 3R01AI166988-05S1 |
| Project ID | NIH-11551510 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with newly diagnosed drug-susceptible pulmonary TB, with and without HIV, who can be followed during standard TB treatment.
✕Less likely to help
Individuals not meeting the TB diagnosis or not within the study’s follow-up window may not benefit.
What this research studies
TB causes long-lasting lung damage and is especially deadly for people with HIV. The INFIN-TB study will follow 250 adults (125 with HIV, 125 without HIV) starting treatment for pulmonary TB to explore inflammatory and fibrotic processes that may lead to post-TB lung disease. Researchers will look at neutrophil-driven inflammation and profibrotic activity early in treatment to see if these pathways predict later lung impairment. The goal is to identify mechanisms and at-risk populations so future therapies can prevent chronic lung disease after TB.
Why it matters
Potential benefit: If successful, findings could guide new strategies to prevent or lessen long-term lung problems after TB, improving quality of life for survivors.
How similar studies have gone: Previous work suggests that early inflammatory and fibrotic pathways may influence post-TB lung disease, but this project tests these relationships prospectively in a larger cohort.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Auld, Sara — Emory University
- Study coordinator: Auld, Sara
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.